ANDAINTRAVENOUSSOLUTION
Approved
May 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MIDAZOLAM IN 0.8% SODIUM CHLORIDE (midazolam in 0.8% sodium chloride) by B. Braun is short-acting benzodiazepine central nervous system (cns) depressant. First approved in 2025.
Drug data last refreshed 1w ago
Mechanism of Action
short-acting benzodiazepine central nervous system (CNS) depressant.
Pharmacologic Class:
Benzodiazepine
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
B. Braun
Germany - Melsungen
Worked on MIDAZOLAM IN 0.8% SODIUM CHLORIDE at B. Braun? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.